Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» $41B for Allergan's generics business? Investors now say Teva 'grossly' overpaid
$41B for Allergan's generics business? Investors now say Teva 'grossly' overpaid
$41B for Allergan's generics business? Investors now say Teva 'grossly' overpaid
Submitted by
admin
on June 1, 2016 - 4:50pm
Source:
Fierce Pharma
News Tags:
Allergan
Teva Pharmaceutical
generics
M&A
Headline:
$41B for Allergan's generics business? Investors now say Teva 'grossly' overpaid
Do Not Allow Advertisers to Use My Personal information
